AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 81 min read$CRSP

KASINGER JAMES R. sold $119K of CRSP

KASINGER JAMES R. (General Counsel and Secretary) sold 1,990 shares of CRISPR Therapeutics AG (CRSP) at $60.04 ($0.12M total) on 2026-10-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · KASINGER JAMES R.
Published Oct 8, 2026, 9:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 9:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CRSP
Neutral
high confidence
Mentioned
$CRSP
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRSPNeutralLow
01

Why it matters

The sale represents a routine liquidity event with limited market impact.

02

Market read

A modest insider sale filed today; unlikely to affect price materially.

03

What to watch

The sale was executed under a 10b5-1 plan, which removes speculation about timing motives.

Relevance 3/10Novelty 3/10Timing: post‑market filing today

Background

Form 4 filings disclose insider transactions and are primary sources for insider activity.

Company-level read

Ticker impact

$CRSPNeutralHigh confidence
Context

General Counsel James R. Kasinger sold 1,990 shares for $119,481 via a 10b5-1 plan, reducing his stake to 94,784 shares.

Expected impact

likely slight pressure as the market prices in the insider sell

Evidence & confidence

The transaction size is small relative to total float and follows a pre‑arranged plan, indicating no new negative information about the company.

Market effects

Sector

Minimal impact on the biotech sector; insider sales are routine.

Regional

None

Global

None

Counterpoint

What could challenge this read

If the insider had a larger stake, the sale could be seen as a lack of confidence, but the modest size suggests routine liquidity needs.

Key entities

  • Individual
    James R. Kasinger

    General Counsel and Secretary of CRISPR Therapeutics AG

  • Company
    CRISPR Therapeutics AG

    Biotech firm developing CRISPR gene‑editing therapies

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CRSP insider trading history →

Related articles

OCT 28
$PRMEHighAI 8/10

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits

Shares of gene-editing companies, including Prime Medicine (PRME), Beam Therapeutics, Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and CRISPR Therapeutics (CRSP), rose after the FDA issued draft guidance to expedite personalized treatments for rare genetic diseases. The new approach allows one application for multiple versions of the same gene-editing treatment. PRME gained 20%, with other companies seeing 4-14% increases.

stocktwits.com2 min
OCT 24
$CRSPMedAI 8/10

Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More

CRISPR Therapeutics (CRSP) reports promising Phase 1a trial data for CTX310, a gene-editing therapy for high LDL and TG levels, with potential market of 40M+ U.S. patients. The company also shares Casgevy's rights with Vertex (VRTX). CTX310's Phase 1b results are expected in November. CRISPR's pipeline includes other candidates like CTX611, but faces risks of setbacks and market adoption challenges.

finance.yahoo.com3 min